Clinical Trial Update: ARX788 in HER2-positive Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of ARX-788 for HER2-positive metastatic breast cancer is described, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARX-788

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HER2-positive, Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING